By 2030 In The US The Cost To Treat Heart Disease Will TripleSuzanne Ffolkes
said the report, titledCardiovascular Disease: A Costly Burden for America.The AHA’s previous projections underestimated the impact of America’s ongoingobesity epidemicon the nation’s heart health.Surging rates of obesity and type 2 diabetes in younger...
Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam Vietnam is in the process of an epidemiological transition, with cardiovascular disease (CVD) now ranked as the leading cause of death. The burden of CVD w... HD Anh,C Dan - 《Health Policy & Planning》...
Potential-and potential pitfalls-of screening newborns for critical congenital heart disease Before discharge from a newborn nursery, most US infants undergo screening for a diverse list of medical conditions. In addition to the newborn metabolic s... JA Taylor,CA Phillipi - 《Jama Pediatrics》 ...
Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83(6):890-896. doi:10.1016/S0002-9149(98)01066-2 PubMedGoogle ScholarCrossref 7. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112(23):...
in health-related outcomes have been documented across many dimensions, including race, gender, age, location, disability status, and sexual orientation. Health inequities can be seen across a wide range of conditions including, hypertension, asthma, diabetes, cancer, mental health, and heart disease...
Results The health system cost of an outpatient cardiac consultation was estimated as 182.4 Indian rupees (INR) (US$2.8) and INR334.8 (US$5.2) in the cardiology, and cardio-thoracic and vascular surgery (CTVS) departments, respectively. The cost of hospitalization per bed-day in cardiology, ...
Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk m... Methodological differences and variations in health care regulations among countries often preclude direct comparisons of cost-effectiveness studies....
This economic evaluation estimates the cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction.
There is growing evidence to support the benefits of transcatheter aortic valve implantation (TAVI) over surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis (sSAS) who are at high- or intermediate-risk of surgical